Compare RAPP & LADR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RAPP | LADR |
|---|---|---|
| Founded | 2022 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Real Estate Investment Trusts |
| Sector | | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2024 | 2013 |
| Metric | RAPP | LADR |
|---|---|---|
| Price | $29.33 | $8.78 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 7 |
| Target Price | ★ $63.04 | $11.79 |
| AVG Volume (30 Days) | 420.4K | ★ 1.5M |
| Earning Date | 11-05-2026 | 10-26-2026 |
| Dividend Yield | N/A | ★ 10.55% |
| EPS Growth | ★ 24.34 | N/A |
| EPS | N/A | ★ 0.14 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $13.72 |
| Revenue Next Year | N/A | $1.89 |
| P/E Ratio | ★ N/A | $62.29 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.75 | $8.48 |
| 52 Week High | $52.93 | $11.48 |
| Indicator | RAPP | LADR |
|---|---|---|
| Relative Strength Index (RSI) | 22.98 | 33.23 |
| Support Level | $26.08 | $8.48 |
| Resistance Level | $31.57 | $10.39 |
| Average True Range (ATR) | 1.63 | 0.17 |
| MACD | -0.13 | 0.01 |
| Stochastic Oscillator | 10.27 | 36.48 |
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
Ladder Capital Corp is an internally-managed real estate investment trust that is in commercial real estate finance. The company originates and invests in a diverse portfolio of commercial real estate and real estate-related assets, focusing on senior secured assets. The company's investment activities include: (i) Primary business of originating senior first mortgage fixed and floating rate loans collateralized by commercial real estate with flexible loan structures; (ii) owning and operating commercial real estate, including net leased commercial properties; and (iii) investing in investment-grade securities secured by first mortgage loans on commercial real estate. The company has three reportable segments: Loans, which derive maximum revenue; Securities; and Real Estate.